AML WITH MUTATED NPM1
Clinical trials for AML WITH MUTATED NPM1 explained in plain language.
Never miss a new study
Get alerted when new AML WITH MUTATED NPM1 trials appear
Sign up with your email to follow new studies for AML WITH MUTATED NPM1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat leukemia: drug combo trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…
Matched conditions: AML WITH MUTATED NPM1
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 12:12 UTC
-
New cell therapy aims to stop blood cancer relapse in tough-to-treat patients
Disease control Recruiting nowThis early-stage trial tests a new cell therapy called BSB-2002 in adults with a specific form of acute myeloid leukemia (AML) that has returned or not responded to at least two prior treatments. The main goal is to check the safety of BSB-2002 and see if it can prevent the cance…
Matched conditions: AML WITH MUTATED NPM1
Phase: PHASE1 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New combo therapy targets tough leukemia gene mutations
Disease control Recruiting nowThis early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…
Matched conditions: AML WITH MUTATED NPM1
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC